Today, Pfizer and BioNTech submitted a request to the Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) of their COVID-19 vaccine candidate. All Americans should be encouraged by this next step towards a safe and effective vaccine. The Pfizer/BioNTech candidate was deemed 95 percent effective based on clinical trial data in a 40,000+ person trial. Now that data, and more, will undergo analysis by FDA professionals and an independent panel of experts. FDA resources on vaccine development and the COVID-19 vaccine EUA process can help answer questions about what this final phase looks like.
National Updates The Food and Drug Administration issued an emergency use authorization for baricitinib, a drug to be used in conjunction with remdesivir for the treatment of COVID-19 in certain hospitalized patients.
The Centers for Medicare & Medicaid Services urges nursing home staff, residents and visitors to adhere to infection prevention guidelines for visitation during the holiday season.
The Centers for Disease Control and Prevention published guidance for safely celebrating Thanksgiving for you to take into consideration as you plan for this year.
